Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Hydromorphone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 known ✓ | P35372 | 5/20 | 1.00 |
| ▸ | OPRD1 | P41143 | 7/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 4/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 0.75 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.75 |
| ▸ | MRGPRX2 | Q96LB1 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydromorphone SCHEMBL17036614 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1LMNAPDE4D | |
| Hydromorphone SCHEMBL16024201 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1LMNAPDE4D | |
| Hydromorphone SCHEMBL19107004 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1LMNAPDE4D | |
| Hydromorphone SCHEMBL16310800 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1LMNAPDE4D | |
| Hydromorphone SCHEMBL2255 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1LMNAPDE4D | |
| Hydromorphone SCHEMBL6798556 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1LMNAPDE4D | |
| Hydromorphone SCHEMBL10031237 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1LMNAPDE4D | |
| Hydromorphone SCHEMBL12368741 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1LMNAPDE4D | |
| Hydromorphone SCHEMBL4978365 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1LMNAPDE4D | |
| Hydromorphone SCHEMBL6744794 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1LMNAPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9585963-B2 | Compositions comprising enzyme-cleavable opioid prodrugs and inhibitors thereof | SIGNATURE THERAPEUTICS, INC. (US) | 2017-03-07 | — | — | US | disclosed |
| US-9585963-B2 | Compositions comprising enzyme-cleavable opioid prodrugs and inhibitors thereof | SIGNATURE THERAPEUTICS, INC. (US) | 2017-03-07 | — | — | US | disclosed |
| US-9534014-B2 | Pharmaceutical compositions with attenuated release of phenolic opioids | SIGNATURE THERAPEUTICS, INC. (US) | 2017-01-03 | — | — | US | disclosed |
| US-20150297736-A1 | Compositions Comprising Enzyme-Cleavable Opioid Prodrugs and Inhibitors Thereof | 3I, LP | 2015-10-22 | — | — | US | disclosed |
| US-20150297736-A1 | Compositions Comprising Enzyme-Cleavable Opioid Prodrugs and Inhibitors Thereof | 3I, LP | 2015-10-22 | — | — | US | disclosed |
| US-9040032-B2 | Compositions comprising enzyme-cleavable opioid prodrugs and inhibitors thereof | SIGNATURE THERAPEUTICS, INC. (US) | 2015-05-26 | — | — | US | disclosed |
| US-9040032-B2 | Compositions comprising enzyme-cleavable opioid prodrugs and inhibitors thereof | SIGNATURE THERAPEUTICS, INC. (US) | 2015-05-26 | — | — | US | disclosed |
| US-20150031635-A1 | Pharmaceutical Compositions with Attenuated Release of Phenolic Opioids | 3I, LP | 2015-01-29 | — | — | US | disclosed |
| US-8802681-B2 | Pharmaceutical compositions with attenuated release of phenolic opioids | SIGNATURE THERAPEUTICS, INC. (US) | 2014-08-12 | — | — | US | disclosed |
| US-20130210701-A1 | Compositions Comprising Enzyme-Cleavable Opioid Prodrugs and Inhibitors Thereof | SIGNATURE THERAPEUTICS, INC. (US) | 2013-08-15 | — | — | US | disclosed |
| US-20130210701-A1 | Compositions Comprising Enzyme-Cleavable Opioid Prodrugs and Inhibitors Thereof | SIGNATURE THERAPEUTICS, INC. (US) | 2013-08-15 | — | — | US | disclosed |
| US-20130210854-A1 | Compositions Comprising Enzyme-Cleavable Prodrugs of Active Agents and Inhibitors Thereof | SIGNATURE THERAPEUTICS, INC. (US) | 2013-08-15 | — | — | US | disclosed |
| US-20130210700-A1 | Compositions Comprising Enzyme-Cleavable Phenol-Modified Opioid Prodrugs and Inhibitors Thereof | SIGNATURE THERAPEUTICS, INC. (US) | 2013-08-15 | — | — | US | disclosed |
| US-20130210854-A1 | Compositions Comprising Enzyme-Cleavable Prodrugs of Active Agents and Inhibitors Thereof | SIGNATURE THERAPEUTICS, INC. (US) | 2013-08-15 | — | — | US | disclosed |
| US-20130210700-A1 | Compositions Comprising Enzyme-Cleavable Phenol-Modified Opioid Prodrugs and Inhibitors Thereof | SIGNATURE THERAPEUTICS, INC. (US) | 2013-08-15 | — | — | US | disclosed |
| US-20110281886-A1 | Pharmaceutical Compositions with Attenuated Release of Phenolic Opioids | 3I, LP | 2011-11-17 | — | — | US | disclosed |
| US-20110262360-A1 | Compositions Comprising Enzyme-Cleavable Phenol-Modified Opioid Prodrugs and Inhibitors Thereof | SIGNATURE THERAPEUTICS, INC. | 2011-10-27 | — | — | US | disclosed |
| US-20110262360-A1 | Compositions Comprising Enzyme-Cleavable Phenol-Modified Opioid Prodrugs and Inhibitors Thereof | SIGNATURE THERAPEUTICS, INC. | 2011-10-27 | — | — | US | disclosed |
| US-20110262359-A1 | COMPOSITIONS COMPRISING ENZYME-CLEAVABLE PRODRUGS OF ACTIVE AGENTS AND INHIBITORS THEREOF | SIGNATURE THERAPEUTICS, INC. | 2011-10-27 | — | — | US | disclosed |
| US-20110262355-A1 | COMPOSITIONS COMPRISING ENZYME-CLEAVABLE OPIOID PRODRUGS AND INHIBITORS THEREOF | SIGNATURE THERAPEUTICS, INC. | 2011-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150031635-A1 | Pharmaceutical Compositions with Attenuated Release of Phenolic Opioids | COMT, OPRM1, OPRK1 | OPRM1 2/4885OPRD1 4/4885OPRK1 3/4885 |
| US-20130210701-A1 | Compositions Comprising Enzyme-Cleavable Opioid Prodrugs and Inhibitors Thereof | ACHE, OPRM1, DNPEP | OPRM1 2/4885OPRD1 6/4885OPRK1 7/4885 |
| US-20110262360-A1 | Compositions Comprising Enzyme-Cleavable Phenol-Modified Opioid Prodrugs and Inhibitors Thereof | COMT, OPRM1, DNPEP | OPRM1 2/4885OPRD1 7/4885OPRK1 5/4885 |
| US-20110262359-A1 | COMPOSITIONS COMPRISING ENZYME-CLEAVABLE PRODRUGS OF ACTIVE AGENTS AND INHIBITORS THEREOF | PEPD, TMPRSS15, ADAM17 | OPRM1 4091/4885OPRD1 4269/4885OPRK1 4344/4885 |
| US-20130210854-A1 | Compositions Comprising Enzyme-Cleavable Prodrugs of Active Agents and Inhibitors Thereof | PEPD, TMPRSS15, ADAM17 | OPRM1 4091/4885OPRD1 4269/4885OPRK1 4344/4885 |
| US-20110262355-A1 | COMPOSITIONS COMPRISING ENZYME-CLEAVABLE OPIOID PRODRUGS AND INHIBITORS THEREOF | ACHE, OPRM1, DNPEP | OPRM1 2/4885OPRD1 6/4885OPRK1 7/4885 |
| US-20110281886-A1 | Pharmaceutical Compositions with Attenuated Release of Phenolic Opioids | COMT, OPRM1, OPRK1 | OPRM1 2/4885OPRD1 4/4885OPRK1 3/4885 |
| US-20130210700-A1 | Compositions Comprising Enzyme-Cleavable Phenol-Modified Opioid Prodrugs and Inhibitors Thereof | COMT, OPRM1, DNPEP | OPRM1 2/4885OPRD1 7/4885OPRK1 5/4885 |
| US-20150297736-A1 | Compositions Comprising Enzyme-Cleavable Opioid Prodrugs and Inhibitors Thereof | ACHE, OPRM1, DNPEP | OPRM1 2/4885OPRD1 6/4885OPRK1 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.